

## Tazorac<sup>®</sup> (tazarotene) – First-time generic

- On September 15, 2022, Cosette launched an [AB-rated](#) generic version of Allergan's [Tazorac \(tazarotene\)](#) gel.
  - Cosette's generic Tazorac gel received 180-days of competitive generic therapy exclusivity.
- Tazorac is approved for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement, and the topical treatment of patients with facial acne vulgaris of mild to moderate severity.
- Tazarotene is also available generically as a [cream](#) and a [foam](#), and a brand lotion ([Arazlo<sup>®</sup>](#)) and a brand combination lotion ([Duobrii<sup>®</sup> \[halobetasol/tazarotene\]](#)).
  - The cream is approved for similar indications as Tazorac gel.
  - The foam is approved for the topical treatment of acne vulgaris in patients 12 years of age or older.
  - Arazlo is approved for the topical treatment of acne vulgaris in patients 9 years of age and older.
  - Duobrii is approved for the topical treatment of plaque psoriasis in adults.